A computerized database is described that contains information about 507 mutations in the p53 gene of hematologic tumors and corresponding cell lines. Analysis of these mutations indicated the following findings: First, mutational spectrum analysis in these tumors was found to be similar to the patt
Analysis of theSmad5 gene in hematological malignancies
β Scribed by Ikezoe, Takayuki; Takeuchi, Seisho; Kobayashi, Makoto; Taguchi, Hirokuni
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 337 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
β¦ Synopsis
FL 33612 to permit rapid consideration for publication.
Recurrent Lymphocytic Pleural Effusion After Intravenous Immunoglobulin
To the Editor: A 35-year-old female was initially diagnosed in 1981 with stage IIA Hodgkin's disease treated successfully with MOPP (mechlorethamine, oncovin, procarbazine, and prednisone) and mantle radiation.
π SIMILAR VOLUMES
The Wilms' tumor gene WT1, whose loss of function accounts for the genesis of about 10% of Wilms' tumors, is expressed in hematopoietic stem cells and leukemia. By analogy with the relationship between the kidney stem cell and Wilms' tumor, it is probable that WT1 is mutated in leukemia. WT1 mutatio
This paper reports on an analysis of nearly 27,000 hematological malignancies diagnosed in the U.K. in the 10-year period 1984 to 1993. The unique observations provided in this analysis are the similarity of the sex-specific curves by age for acute myeloid leukemia, myelodysplasia types, polycythemi
Several partner genes on different chromosomes have been reported to be fused with the ETV6 gene (located in chromosome band 12p13), with different breakpoints and different frequencies, in various hematologic malignancies, particularly acute myeloid and lymphoid leukemias and myelodysplastic syndro
## Abstract Several side effects of interferonβΞ±β2b (IFNβΞ±) therapy have been described. Pulmonary side effects have seldom been reported. The four patients we describe all developed respiratory disorders while being treated with IFNβΞ± for hematological malignancies. We point out the similarities a